Stock GOSS GOSSAMER BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.694 USD -4.93% Intraday chart for Gossamer Bio, Inc. -6.51% -23.95%
May. 07 Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 06 Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 953.2 701 854.3 204.5 205.7 157 - -
Enterprise Value (EV) 1 579.8 360.8 708.2 168.2 118.3 224.5 283.6 176.8
P/E ratio -4.75 x -2.72 x -3.61 x -0.8 x -0.77 x -1.74 x -0.92 x -1.73 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - 1.37 x 37.6 x 2.84 x
EV / Revenue - - - - - 1.96 x 68 x 3.2 x
EV / EBITDA -3.13 x -1.55 x -3.3 x -0.78 x -0.65 x -18.1 x -1.67 x -1.69 x
EV / FCF -3.92 x -2.03 x -3.72 x -0.9 x -0.74 x 19.5 x -2.87 x -12.5 x
FCF Yield -25.5% -49.3% -26.9% -111% -135% 5.12% -34.8% -8.03%
Price to Book 2.43 x - - 17 x 3.28 x -1.79 x -1.61 x -8.25 x
Nbr of stocks (in thousands) 60,985 72,496 75,538 94,256 225,409 226,219 - -
Reference price 2 15.63 9.670 11.31 2.170 0.9125 0.6940 0.6940 0.6940
Announcement Date 3/24/20 2/25/21 3/3/22 3/17/23 3/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 114.3 4.171 55.2
EBITDA 1 -185.2 -232.6 -214.4 -216.8 -182.2 -12.42 -170.3 -104.7
EBIT 1 -186.1 -234 -216.1 -218.6 -183.8 -82.5 -182.4 -116
Operating Margin - - - - - -72.19% -4,371.5% -210.08%
Earnings before Tax (EBT) 1 -180.3 -243.4 -234 -229.4 -179.8 -76.93 -181.7 -113
Net income 1 -180.3 -243.4 -234 -229.4 -179.8 -71.74 -188 -118.7
Net margin - - - - - -62.77% -4,507.7% -215.09%
EPS 2 -3.290 -3.550 -3.130 -2.710 -1.180 -0.3998 -0.7582 -0.4019
Free Cash Flow 1 -147.8 -177.9 -190.4 -187.4 -159.2 11.5 -98.8 -14.2
FCF margin - - - - - 10.06% -2,368.49% -25.73%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/24/20 2/25/21 3/3/22 3/17/23 3/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - 114.3 - - -
EBITDA 1 -55.21 -51.21 -53.89 -53.41 -55.56 -53.9 -47.48 -45.8 -40.1 -48.74 -35.2 123.7 -36.4 -37.5 -
EBIT 1 -55.66 -51.66 -54.34 -53.87 -56.02 -54.36 -47.94 -46.3 -40.49 -49.03 -41.96 48.54 -43.83 -45.24 -48.18
Operating Margin - - - - - - - - - - - 42.47% - - -
Earnings before Tax (EBT) 1 -60.25 -56.28 -57.78 -56.47 -59.36 -55.76 -49.16 -42.5 -40.01 -48.15 -41.93 53.69 -43.58 -44.91 -51.26
Net income 1 -60.25 -56.28 -57.78 -56.47 -59.36 -55.76 -49.16 -42.5 -40.01 -48.15 -41.93 61.68 -45.15 -47.01 -51.26
Net margin - - - - - - - - - - - 53.97% - - -
EPS 2 -0.8000 -0.7400 -0.7600 -0.7400 -0.6500 -0.5900 -0.5200 -0.4500 -0.2100 -0.2100 -0.1900 0.2733 -0.1933 -0.1967 -0.1951
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/8/21 3/3/22 5/10/22 8/9/22 11/3/22 3/17/23 5/9/23 8/8/23 11/9/23 3/5/24 5/7/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 67.6 127 19.8
Net Cash position 1 373 340 146 36.4 87.4 - - -
Leverage (Debt/EBITDA) - - - - - -5.44 x -0.7434 x -0.1891 x
Free Cash Flow 1 -148 -178 -190 -187 -159 11.5 -98.8 -14.2
ROE (net income / shareholders' equity) -155% -72.3% -106% -344% -480% - - -
ROA (Net income/ Total Assets) - - - -74.5% - - - -
Assets 1 - - - 308.1 - - - -
Book Value Per Share 2 6.440 - - 0.1300 0.2800 -0.3900 -0.4300 -0.0800
Cash Flow per Share -2.650 -2.570 -2.520 -2.210 - - - -
Capex 1 2.97 1.5 1.55 0.41 - 0.5 1.89 2.12
Capex / Sales - - - - - 0.44% 45.24% 3.84%
Announcement Date 3/24/20 2/25/21 3/3/22 3/17/23 3/5/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
0.694 USD
Average target price
6.094 USD
Spread / Average Target
+778.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GOSSAMER BIO, INC. Stock Gossamer Bio, Inc.
-23.95% 157M
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GOSS Stock
  4. Financials Gossamer Bio, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW